ADVANCE ONLINE PUBLICATION

RESEARCH HIGHLIGHTS

Prometheus 2.0: drug-induced liver regeneration arising

Jan S. Tchorz

Biomedical Research, Novartis Pharma AG, Basel, Switzerland
* Correspondence: Jan S. Tchorz(jan.tchorz@novartis.com)

In a recent publication in Cell, a multidisciplinary academic drug discovery team, with its spin-off HepaRegeniX, published a first-in-class small molecule MKK4 inhibitor (HRX215) with remarkable efficacy in multiple preclinical liver regeneration models and positive first-in-human data. Its potential to prevent liver failure and boost regeneration may provide a novel therapeutic avenue for many patients with liver disease.

https://doi.org/10.1038/s41422-024-00965-w

FULL TEXT | PDF

Browse 34